^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    AVENIO ctDNA Targeted Kit

    Company:
    Roche
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    7ms
    OSIRIS: Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed. (clinicaltrials.gov)
    P=N/A; Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    AVENIO ctDNA Targeted Kit
    |
    Tagrisso (osimertinib)